Difference between revisions of "ELF3-AS1"

From LncRNAWiki
Jump to: navigation, search
(Created page with "==Annotated Information== ===Approved Symbol=== ELF3-AS1 ===Approved Name=== ELF3 antisense RNA 1 ===Previous Symbols=== _ ===Synonyms=== ENST00000415582 ===Chromosome=== 1q32...")
 
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 +
 
==Annotated Information==
 
==Annotated Information==
−
===Approved Symbol===
+
===Name===
−
ELF3-AS1
+
Approved symbol: ELF3-AS1:ELF3 antisense RNA 1
−
===Approved Name===
+
 
−
ELF3 antisense RNA 1
+
Approved symbol: ENST00000415582 <ref name="ref1" />, SCAT7
−
===Previous Symbols===
+
 
−
_
+
HGNC ID: HGNC:40211
−
===Synonyms===
+
 
−
ENST00000415582
+
LncBook transcript ID: HSALNT0288941
−
===Chromosome===
+
===Function===
−
1q32.1
+
ELF3-AS1 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-131I-avid lung metastases from Papillary Thyroid Cancer(PTC) <ref name="ref1" />. ELF3-AS1 has high diagnostic sensitivity and specificity for predicting non-131I-avid lung metastases of PTC, and low ELF3-AS1 lncRNA level is associated with better prognosis of PTC patients with lung metastases (P<0.001) <ref name="ref1" />.
−
===RefSeq ID===
+
 
−
_
+
Depletion of SCAT7 in Caki-2 cells altered cell proliferation, inhibited cell cycle progression, and induced apoptosis. SCAT7 interacts with hnRNPK/YBX1 complex and affects cancer cell hallmarks through the regulation of FGF/FGFR and its downstream PI3K/AKT and MAPK pathways<ref name="ref2" />.
−
===OMIM ID===
+
===Expression===
−
_
+
[[File:ENST00000415582.JPG|right|thumb|400px|'''Expression of ELF3-AS1 in Papillary Thyroid Cancer patients''' <ref name="ref1" />.]]
−
===RefSeq(supplied by NCBI)===
+
ELF3-AS1 is significantly upregulated in samples from the non-131I-avid lung metastasis group comparing with 131I-avid lung metastasis group(p<0.05) <ref name="ref1" />.
−
XR_426886
+
 
−
===pubmed IDs===
+
SCAT7 was upregulated in multiple cancers (BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC). The temporal expression analysis of SCAT7 during cell cycle progression indicated elevated levels in the S-phase of HeLa and Caki-2 cell lines<ref name="ref2" />.
−
27997908
+
===Diseases===
 +
Papillary Thyroid Cancer <ref name="ref1" />
 +
 
 +
Multiple cancers including BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC<ref name="ref2" />.
 +
===Sequence===
 +
>XR_426886.2 PREDICTED: Homo sapiens uncharacterized LOC102723465 (LOC102723465), ncRNA
 +
<dnaseq>AATACTCATGGATTAATTGGTGCTGGCTGGGCCTGCCAGCCTAGTCGTGGCCCCAGGGTCCCCACTAAAG
 +
GGCTCCTTCTCCAGCGCCCACTCTGTTGGCAAGGTCTTCACTACCATCACCTGCCTGGACTCCATCCAAG
 +
CATCAGGGTTGCTGCAGTCGCTCCTGAAGAGACCCGGCTCTGCTTGAAAGTTCTTCCCTCAGCGCCTGCT
 +
GGAGCCCTCCCTGCCGGAGTTGCCAGAATCCACACGGAATCCACAGATCTGCCCTGATGATCATGAAGGA
 +
ATGCGAAAGAGCCTGGTAAAACGATATGGACTTGTGCAAATGCAAAGCAATGGTGAAGTCATCACGAACC
 +
GCACAGACTGGACAGAACTCCTATCTGGCTGCAATGGCTTGGGTTCAGTCAGCCCAGGGGCCAGAGAATT
 +
GGCTACAAAGAGCTCTGGAGTGCCCCTCCCTCCAAATAAAGTATTCTAAGCGTGCACTGA</dnaseq>
 +
==Labs working on this lncRNA==
 +
*Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
 +
*Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden.
 +
==References==
 +
<references>
 +
<ref name="ref1">
 +
Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ, Luo QY. Circulating Long
 +
Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in
 +
Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem.
 +
2016;40(6):1377-1390.
 +
</ref>(1)
 +
<ref name="ref2">
 +
Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T, Kanduri C. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018 Feb 28;9(1):883. doi: 10.1038/s41467-018-03265-1.
 +
</ref>(2)
 +
</references>

Latest revision as of 05:15, 7 August 2019

Annotated Information

Name

Approved symbol: ELF3-AS1:ELF3 antisense RNA 1

Approved symbol: ENST00000415582 [1], SCAT7

HGNC ID: HGNC:40211

LncBook transcript ID: HSALNT0288941

Function

ELF3-AS1 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-131I-avid lung metastases from Papillary Thyroid Cancer(PTC) [1]. ELF3-AS1 has high diagnostic sensitivity and specificity for predicting non-131I-avid lung metastases of PTC, and low ELF3-AS1 lncRNA level is associated with better prognosis of PTC patients with lung metastases (P<0.001) [1].

Depletion of SCAT7 in Caki-2 cells altered cell proliferation, inhibited cell cycle progression, and induced apoptosis. SCAT7 interacts with hnRNPK/YBX1 complex and affects cancer cell hallmarks through the regulation of FGF/FGFR and its downstream PI3K/AKT and MAPK pathways[2].

Expression

Expression of ELF3-AS1 in Papillary Thyroid Cancer patients [1].

ELF3-AS1 is significantly upregulated in samples from the non-131I-avid lung metastasis group comparing with 131I-avid lung metastasis group(p<0.05) [1].

SCAT7 was upregulated in multiple cancers (BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC). The temporal expression analysis of SCAT7 during cell cycle progression indicated elevated levels in the S-phase of HeLa and Caki-2 cell lines[2].

Diseases

Papillary Thyroid Cancer [1]

Multiple cancers including BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC[2].

Sequence

>XR_426886.2 PREDICTED: Homo sapiens uncharacterized LOC102723465 (LOC102723465), ncRNA

000001 AATACTCATG GATTAATTGG TGCTGGCTGG GCCTGCCAGC CTAGTCGTGG CCCCAGGGTC CCCACTAAAG GGCTCCTTCT 000080
000081 CCAGCGCCCA CTCTGTTGGC AAGGTCTTCA CTACCATCAC CTGCCTGGAC TCCATCCAAG CATCAGGGTT GCTGCAGTCG 000160
000161 CTCCTGAAGA GACCCGGCTC TGCTTGAAAG TTCTTCCCTC AGCGCCTGCT GGAGCCCTCC CTGCCGGAGT TGCCAGAATC 000240
000241 CACACGGAAT CCACAGATCT GCCCTGATGA TCATGAAGGA ATGCGAAAGA GCCTGGTAAA ACGATATGGA CTTGTGCAAA 000320
000321 TGCAAAGCAA TGGTGAAGTC ATCACGAACC GCACAGACTG GACAGAACTC CTATCTGGCT GCAATGGCTT GGGTTCAGTC 000400
000401 AGCCCAGGGG CCAGAGAATT GGCTACAAAG AGCTCTGGAG TGCCCCTCCC TCCAAATAAA GTATTCTAAG CGTGCACTGA 000480

Labs working on this lncRNA

  • Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
  • Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ, Luo QY. Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. 2016;40(6):1377-1390.
  2. ↑ 2.0 2.1 2.2 Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T, Kanduri C. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018 Feb 28;9(1):883. doi: 10.1038/s41467-018-03265-1.
Retrieved from "https://ngdc.cncb.ac.cn/lncrnawiki1/index.php?title=ELF3-AS1&oldid=1276067"